BioCentury
ARTICLE | Finance

Funding roundup: F-Prime leads series A for Toronto Dx company Adela; plus fresh funding for Strand, Tvardi, Orum, Glycomine and HutchMed

Meanwhile, digital biotech Pear readies for SPAC

June 24, 2021 2:10 AM UTC

Fresh money continues to swell the coffers of private start-ups such as blood-based cancer detection company Adela and mRNA play Strand as well as veteran companies such as dual-listed HutchMed, which raised more than $500 million in a global offering Wednesday.

Toronto-based Adela (formerly DNAMx) raised $60 million in a series A round led by F-Prime Capital. The company believes its incorporation of genome-wide methylation enrichment technology could lead to a best-in-class test that can detect multiple diseases using a single assay...